The failure of torcetrapib: was it the molecule or the mechanism?
Tall
Alan R
AR
Yvan-Charvet
Laurent
L
Wang
Nan
N
D000787:Angina Pectoris / Q000209:etiology; D000818:Animals; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000069059:Atorvastatin; D002303:Cardiac Output, Low / Q000209:etiology; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008076:Cholesterol, HDL / Q000378:metabolism; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D009204:Myocardial Revascularization; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects* / Q000627:therapeutic use*; D011817:Rabbits; D017211:Treatment Failure
D000924:Anticholesteremic Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D006538:Heptanoic Acids; D011758:Pyrroles; D011804:Quinolines; C483909:torcetrapib; D000069059:Atorvastatin